US EditionAlvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to ...
- On June 5, 2025, Alvotech and Dr. Reddy's Laboratories announced a partnership to jointly develop, produce, and market a biosimilar version of Merck’s Keytruda for distribution worldwide.
- The collaboration leverages the biosimilar expertise of both companies and their mutual commitment to oncology, focusing on pembrolizumab, a leading immuno-oncology drug that achieved global sales of $29.5 billion in 2024.
- The collaboration combines Dr. Reddy's India-based biologics experience and Alvotech's Icelandic biotech platform to expedite development, extend global reach, and share costs and manufacturing responsibilities.
- Róbert Wessman, Alvotech CEO, stated the deal leverages their dedicated R&D and expands their pipeline, while Dr. Reddy's CEO Erez Israeli emphasized the enhancement of oncology capabilities through this biosimilar collaboration.
- The agreement implies increased availability of affordable cancer biologics worldwide but carries uncertainties from clinical trials, regulatory actions, physician preferences, and competition from other generics.
14 Articles
14 Articles
Hastings Tribune
Enid News & EagleAlvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to ...
HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: 500124
Alvotech, Dr Reddy’s partner to develop Keytruda Biosimilar
Alvotech and Dr Reddy’s Laboratories announced today they have entered a collaboration agreement to co-develop, manufacture and commercialise a biosimilar candidate to Keytruda (pembrolizumab) for global markets.
Dr Reddy’s, Alvotech partner to develop and commercialize biosimilar of cancer drug Keytruda
Dr Reddy’s Laboratories announced that it has partnered with Alvotech, to co-develop, manufacture, and sell a biosimilar version of Keytruda (pembrolizumab), for global markets.
Coverage Details
Bias Distribution
- 43% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
